cepharanthine has been researched along with Infarction, Middle Cerebral Artery in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, F; Liang, Q; Liang, S; Piao, X; Shao, S; Wu, Y; Zhao, D; Zhao, J | 1 |
1 other study(ies) available for cepharanthine and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Cepharanthine attenuates cerebral ischemia/reperfusion injury by reducing NLRP3 inflammasome-induced inflammation and oxidative stress via inhibiting 12/15-LOX signaling.
Topics: Animals; Benzylisoquinolines; Brain; Dose-Response Relationship, Drug; Homeodomain Proteins; Infarction, Middle Cerebral Artery; Inflammasomes; Inflammation; Interleukin-18; Interleukin-1beta; Male; Mice; Microglia; Nerve Tissue Proteins; NLR Family, Pyrin Domain-Containing 3 Protein; Oxidative Stress; Reperfusion Injury | 2020 |